Osteonecrosis Clinical Trial
Official title:
Double Blind, Phase I, Randomized, Parallel Group Study of Hip Decompression Compared to Hip Decompression Supplemented at the Point of Care With Adipose Derived Regenerative Cells for Bilateral Pre-Collapse Femoral Head Osteonecrosis
Verified date | December 2021 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized clinical trial aims to determine if cells from a patient's own adipose tissue is safe and capable of helping regenerate the femoral head in patients with osteonecrosis. The standard of care is known as hip decompression which simply removes dead tissue from the femoral head and creates a new cavity to be filled in by healthy bone. This trial will use hip decompression in one hip and hip decompression supplemented with adipose derived regenerative cells in patients with osteonecrosis in both of their hips.
Status | Terminated |
Enrollment | 8 |
Est. completion date | June 28, 2021 |
Est. primary completion date | June 28, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years to 70 Years |
Eligibility | Inclusion Criteria - Males and females 22-70 years of age. - No articular surface collapse of the femoral heads as measured by MRI. - Target disease or condition: Bilateral pre-collapse osteonecrosis of the femoral head. - Atraumatic osteonecrosis of the femoral head (all other etiologies eligible including corticosteroid and alcohol induced osteonecrosis). - Ability to safely undergo liposuction that will result in the harvest of a sufficient quantity of adipose tissue (approximately 360 mL). A plastic surgeon evaluation will be performed in order to determine adequate adipose tissue is available for harvest. - Capacity to provide informed consent - Ability to comply with protocol - Normal laboratory values of CBC, CRP, AST, ALT, Bilirubin (total & direct), BUN and Creatinine. Exclusion Criteria: - Post traumatic femoral head osteonecrosis. - Osteonecrosis of the femoral head in stages = IIIA according to the Steinberg classification. - Asymptomatic osteonecrosis on exam - Flattening of the femoral head (Steinberg classification Type IV) or articular cartilage collapse at the time of core decompression surgery. - Septic arthritis, stress fracture, or non-osteonecrosis metabolic bone diseases (e.g., Paget's disease of bone, osteogenesis imperfecta, primary hyperparathyroidism, osteopetrosis, and fibrous dysplasia including monostotic, polyostotic, and McCune-Albright syndrome). - Skeletal immaturity. - Known history of HIV, or has active Hepatitis B or active Hepatitis C. - Disease or medication-related disorder of coagulation (i.e., elevated PTT >13.8 seconds, INR >1.2, or low platelet count <150x109/L). Patients on coumadin, heparin products, and novel oral anticoagulants will be excluded. Antiplatelet medications (e.g. aspirin, clopidogrel) are permitted as long as the aforementioned coagulation labs are within the specified range. - Patients who have aPTT values greater than or equal to 1.8 times the normal limit. - Patients who are actively or recently received glycoprotein IIb/IIIa inhibitors (abciximab/ ReoPro, Aggrastat/ tirofiban, eptifibatide/ Integrilin) - All patients who have inadequate fat deposits (i.e. < 200 ml of lipoaspirate from 3 bilateral sites) will be excluded from the study. - Lumbar radiculopathy, and/or neurogenic or vascular claudication. - Active Skin infection at the time of surgery - Active Local bone infection - Patients in active treatment for cancer or a blood dyscrasia, or having received chemotherapy, radiotherapy or immunotherapy in past 1 year. - Participation in another clinical study in the past 30 days or concurrent participation in another clinical trial. - MRI-incompatible internal devices (pacemakers, aneurysm clips, etc). - Patients with poorly controlled diabetes mellitus (HbA1C = 8%), peripheral neuropathy, or severe vascular problems. - Patients receiving treatment with hematopoietic growth factors or antivasculogenesis or anti-angiogenesis treatment (e.g., anti-VEGF). - Patients requiring bisphosphonate treatment for study duration. - Pregnant or lactating female patients. - Prisoners. - Known starch or gentamycin allergy - Known amylase deficiency - Laser- or ultrasound-assisted lipoaspiration technique is used during the lipoaspiration procedure - An adverse event that meets one or more fat harvest stopping rules has occurred during the lipoaspiration procedure - Positive gram stain result on ADRC product prior to administration - If final viable cell count of ADRC product is < 34 million |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety, as measured by the type and number of serious adverse events related to Hip Decompression supplemented with autologous ADRC transplantation compared to Hip Decompression alone. | Serious adverse events will only include those that are determined to be related to the transplantation of ADRC and/or Hip Decompression. | End of the study (24 months) | |
Secondary | In vitro laboratory metrics as measured by flow analysis as well as proliferation and differentiation potential of adipose and bone marrow derived mesenchymal stem cells (MSCs). | These immunophenotypic characterizations will be correlated with MRI imaging data and patient reported outcomes. | Preoperative, Month 12, and Month 24 | |
Secondary | Initial signals of efficacy as measured by MRI lesion volume quantification and patient reported outcome metrics. | Preoperative MRI, 1 and 2 year postoperative MRI osteonecrotic lesion volume size compared to quality of life and hip function scores.
The five subscales include 10 items on pain, 5 items for symptoms (3 symptoms items, 2 stiffness items) 17 items for activities for daily living (ADLs), 4 items for sports and recreations, and 4 items for hip related quality of life. Scoring: Each question contains five answer choices ranging from never (score of 0) to extreme (score of 4). A normalized score is calculated for each subscale with 0 indicating extreme symptoms and 100 representing no symptoms. |
Preoperative, Month 12, and Month 24 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04072055 -
MOTO Post-marketing Surveillance Study
|
||
Terminated |
NCT02941666 -
Human Mesenchymal Stem Cells in the Synovial Fluid of the Hip
|
||
Terminated |
NCT01763684 -
Oxford Signature vs. Conventional Global Study
|
N/A | |
Completed |
NCT00505219 -
Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head
|
Phase 3 | |
Withdrawn |
NCT02632903 -
Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study
|
Phase 2 | |
Active, not recruiting |
NCT01458782 -
ACI-C Versus AMIC. A Randomized Trial Comparing Two Methods for Repair of Cartilage Defects in the Knee
|
N/A | |
Completed |
NCT01583465 -
Efficacy of Aquamantys for Reducing Transfusions With Anterior Supine Intermuscular Approach Total Hip Arthroplasty
|
N/A | |
Active, not recruiting |
NCT04401267 -
Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma
|
Phase 2 | |
Completed |
NCT03197623 -
Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids
|
Phase 1 | |
Active, not recruiting |
NCT05283148 -
Sickle Cell Disease (SCD) Bone Pain Study
|
N/A | |
Completed |
NCT05684588 -
Post-COVID-19 Sequelae: Osteonecrosis of Femoral Head
|
N/A | |
Completed |
NCT00913679 -
A Comparison of Two Different Surgical Techniques in Hip Resurfacing Arthroplasty
|
N/A | |
Enrolling by invitation |
NCT02893293 -
Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI
|
Phase 4 | |
Completed |
NCT01345097 -
A Short Metaphyseal Fitting Total Hip Arthroplasty in Young and Elderly Patients
|
Phase 4 | |
Recruiting |
NCT00260897 -
Molecular Genetic Study of Avascular Necrosis of the Femoral Head
|
N/A | |
Not yet recruiting |
NCT06016634 -
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
|
Phase 2 | |
Completed |
NCT02077647 -
Focused Registry on the Conservative Treatment of Osteoarthritis of the Knee
|
||
Recruiting |
NCT01619124 -
Osteonecroses in Pediatric Patients With ALL
|
N/A | |
Completed |
NCT02458937 -
Functional Outcomes Following Hip Core Decompression in Younger Participants With Osteonecrosis
|
||
Recruiting |
NCT02661139 -
Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction
|